BioCryst Pharmaceuticals

Yahoo Finance • 8 days ago

Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 25 days ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees restricted... Full story

Yahoo Finance • 28 days ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * ON Semiconductor Corporation (ON [https://seekingalpha.com/symbol/ON]) * Oxford Lane Capital Corp. (OXLC [https://seekingalpha.com/symbol/OXLC]) * fuboTV (FUBO [https://se... Full story

Yahoo Finance • last month

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sotherly Hotels Inc. (Nasdaq – SOHO), Hologic, Inc. (Nasdaq – HOLX), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)

BALA CYNWYD, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • last month

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. (Nasdaq – HOLX), TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)

BALA CYNWYD, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • last month

Key deals this week: Paramount Skydance, PotlatchDeltic, Brighthouse Financial, Papa John's and more

Here's a list of key deals reported across sectors this week: * Paramount Skydance (NASDAQ:PSKY [https://seekingalpha.com/symbol/PSKY]) is preparing a second bid [https://seekingalpha.com/news/4503595-paramount-skydance-preparing-second... Full story

Yahoo Finance • last month

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)

BALA CYNWYD, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 2 months ago

BioCryst to buy Astria Therapeutics for $13 per share (update)

_UPDATE: ADDS SHARE MOVEMENTS_ BioCryst Pharmaceuticals (NASDAQ:BCRX [https://seekingalpha.com/symbol/BCRX]) has agreed to acquire biopharmaceutical firm Astria Therapeutics (NASDAQ:ATXS [https://seekingalpha.com/symbol/ATXS]) for a mix o... Full story

Yahoo Finance • 2 months ago

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – Bio... Full story

Yahoo Finance • 2 months ago

BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best stocks to buy under $20. On October 1, BioCryst Pharmaceuticals announced the successful completion of the previously announced sale of its European ORLADEYO (berotralstat) bus... Full story

Yahoo Finance • 2 months ago

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

– Transaction valued at $250 million, with up to $14 million in future milestones – – BioCryst will focus on driving ORLADEYO sales in the U.S. while Neopharmed Gentili will lead commercialization across Europe – – Provides a significant... Full story

Yahoo Finance • 3 months ago

BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September... Full story

Yahoo Finance • 4 months ago

BioCryst Announces Departure of Dr. Helen Thackray

RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and t... Full story

Yahoo Finance • 4 months ago

BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ...

Total Revenue: $163.4 million for Q2 2025. ORLADEYO Revenue: $156.8 million, with $140.3 million generated in the US. ORLADEYO Revenue Growth: 45% increase year-over-year for Q2. Non-GAAP Operating Expenses: $106.4 million for Q2 2025, up... Full story

Yahoo Finance • 4 months ago

BioCryst Pharma soars 6.4% as Q2 results crush expectations

Investing.com -- BioCryst Pharmaceuticals , Inc. (NASDAQ:BCRX) shares surged 6.4% after the company reported second-quarter earnings that significantly exceeded analyst expectations, driven by record-breaking sales of its hereditary angio... Full story

Yahoo Finance • 4 months ago

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Exceeds Q2 2025 Expectations with Robust Revenue and Profit Growth

BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX [https://www.chartmill.com/stock/quote/BCRX]) SURPASSES Q2 2025 ESTIMATES WITH STRONG REVENUE AND PROFIT GROWTH BioCryst Pharmaceuticals Inc (NASDAQ:BCRX [https://www.chartmill.com/stock/quote/BCR... Full story

Yahoo Finance • 4 months ago

BioCryst: Q2 Earnings Snapshot

DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — BioCryst Pharmaceuticals Inc. (BCRX) on Monday reported second-quarter net income of $5.1 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Durham, North C... Full story

Yahoo Finance • 4 months ago

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

BioCryst Pharmaceuticals, Inc. —Q2 2025 ORLADEYO net revenue of $156.8 million (+45 percent y-o-y)— —Q2 2025 operating profit of $29.8 million (+239 percent y-o-y); non-GAAP operating profit of $57.0 million (+160 percent y-o-y)— —Compa... Full story

Yahoo Finance • 4 months ago

Stocks Set to Open Higher as Investors Bet on Fed Rate Cuts

September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are up +0.64%, and September Nasdaq 100 E-Mini futures (NQU25 [https://www.barchart.com/futures/quotes/NQU25/overview]) are up +0.77% this morning, po... Full story

Yahoo Finance • 4 months ago

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his inte... Full story